Stock A217330 CYTOGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cytogen, Inc.

Equities

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
12,360 KRW -3.74% Intraday chart for Cytogen, Inc. -1.51% -8.58%
Mar. 20 Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors CI
Mar. 18 Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 355,717 289,471 257,276
Enterprise Value (EV) 1 344,539 297,974 219,964
P/E ratio -31.8 x -15.2 x -15.7 x
Yield - - -
Capitalization / Revenue 1,023 x 380 x 80.8 x
EV / Revenue 990 x 392 x 69.1 x
EV / EBITDA -29.3 x -29.3 x -22.3 x
EV / FCF - 71,871,113 x -16,016,607 x
FCF Yield - 0% -0%
Price to Book 15.5 x 51 x 5.63 x
Nbr of stocks (in thousands) 17,437 17,869 19,029
Reference price 2 20,400 16,200 13,520
Announcement Date 3/17/23 3/17/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 347.8 760.8 3,184
EBITDA 1 -11,747 -10,184 -9,880
EBIT 1 -12,861 -11,497 -11,792
Operating Margin -3,697.31% -1,511.28% -370.3%
Earnings before Tax (EBT) 1 -13,323 -18,692 -16,179
Net income 1 -10,871 -18,771 -15,770
Net margin -3,125.13% -2,467.37% -495.22%
EPS 2 -642.0 -1,063 -862.3
Free Cash Flow - 4,146 -13,734
FCF margin - 544.96% -431.28%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 3/17/23 3/17/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - 8,502 -
Net Cash position 1 11,179 - 37,311
Leverage (Debt/EBITDA) - -0.8349 x -
Free Cash Flow - 4,146 -13,734
ROE (net income / shareholders' equity) - -131% -53.4%
ROA (Net income/ Total Assets) - -14.9% -12.7%
Assets 1 - 126,365 123,754
Book Value Per Share 2 1,315 318.0 2,401
Cash Flow per Share 2 1,731 892.0 2,468
Capex 1 1,219 646 2,498
Capex / Sales 350.43% 84.89% 78.45%
Announcement Date 3/17/23 3/17/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
CYTOGEN, INC. Stock Cytogen, Inc.
-8.58% 209M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.11% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+46.99% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-33.09% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.15% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-25.99% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+19.16% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 733M
CAREDX, INC Stock CareDx, Inc
-31.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-43.67% 383M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A217330 Stock
  4. Financials Cytogen, Inc.